Cogent Biosciences, Inc. $COGT Shares Purchased by Pictet Asset Management Holding SA

Posted by Francis Steltz on Jun 30th, 2026

Pictet Asset Management Holding SA increased its position in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 1,499.2% in the first quarter, HoldingsChannel.com reports. The fund owned 1,798,768 shares of the technology company’s stock after buying an additional 1,686,292 shares during the period. Pictet Asset Management Holding SA’s holdings in Cogent Biosciences were worth $68,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Cogent Biosciences by 1,164.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after purchasing an additional 652 shares during the period. Global Retirement Partners LLC purchased a new position in Cogent Biosciences during the 4th quarter worth approximately $37,000. PNC Financial Services Group Inc. raised its position in Cogent Biosciences by 414.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after buying an additional 1,032 shares during the last quarter. GAMMA Investing LLC lifted its stake in Cogent Biosciences by 91.7% during the 4th quarter. GAMMA Investing LLC now owns 1,369 shares of the technology company’s stock valued at $49,000 after acquiring an additional 655 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Cogent Biosciences by 3,845.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,736 shares of the technology company’s stock valued at $62,000 after acquiring an additional 1,692 shares during the period.

Cogent Biosciences Stock Up 1.7%

COGT stock opened at $38.74 on Tuesday. The firm has a market cap of $6.62 billion, a PE ratio of -17.85 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. The firm’s fifty day moving average is $34.54 and its 200 day moving average is $36.27. Cogent Biosciences, Inc. has a one year low of $7.07 and a one year high of $43.73.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.53). On average, research analysts forecast that Cogent Biosciences, Inc. will post -2.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on COGT shares. HC Wainwright increased their price objective on shares of Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Jefferies Financial Group started coverage on Cogent Biosciences in a research note on Monday, March 16th. They set a “buy” rating and a $55.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a research note on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.73.

Read Our Latest Stock Analysis on Cogent Biosciences

Cogent Biosciences Company Profile

(Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.